kwic
treatment
treatment
right
off
ON
32
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for treatment out of >500 occurrences
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to treatment]
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
| 32) The bone marrow is a frequent location of primary relapse after conventional cytotoxic drug treatment of human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). |
| PMID:34591931 DOI:10.1371/journal.pone.0258140 |
| 2021 PloS one |
| * Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence. |
| - The bone marrow is a frequent location of primary relapse after conventional cytotoxic drug treatment of human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Because stromal cells have a major role in promoting chemotherapy resistance, they should be included to more realistically model in vitro drug treatment. Here we validated a novel application of the xCELLigence system as a continuous co-culture to assess long-term effects of drug treatment on BCP-ALL cells. We found that bone marrow OP9 stromal cells adhere to the electrodes but are progressively displaced by dividing patient-derived BCP-ALL cells, resulting in reduction of impedance over time. Death of BCP-ALL cells due to drug treatment results in re-adherence of the stromal cells to the electrodes, increasing impedance. Importantly, vincristine inhibited proliferation of sensitive BCP-ALL cells in a dose-dependent manner, correlating with increased impedance. This system was able to discriminate sensitivity of two relapsed Philadelphia chromosome (Ph) positive ALLs to four different targeted kinase inhibitors. Moreover, differences in sensitivity of two CRLF2-drivenBCP-ALL cell lines to ruxolitinib were also seen. These results show that impedance can be used as a novel approach to monitor drug treatment and sensitivity of primary BCP-ALL cells in the presence of protective microenvironmental cells. |
[
right
kwic]
(1)68  of |
(13)7 planning |
(25)3 outcome |
(37)2 efficacy |
| (2)50 *null* | (14)6 to |
(26)3 protocols |
(38)2 goals |
| (3)29 and |
(15)4 approaches |
(27)3 that |
(39)2 group |
| (4)23 for |
(16)4 methods |
(28)2 a |
(40)2 groups |
| (5)22 with |
(17)4 option |
(29)2 as |
(41)2 may |
| (6)15 options |
(18)4 options, |
(30)2 at |
(42)2 ranks |
| (7)13 in |
(19)4 ranking |
(31)2 being |
(43)2 reduced |
| (8)9 effect |
(20)4 regimens |
(32)2 compared |
(44)2 resistance |
| (9)9 effects |
(21)4 strategies |
(33)2 decisions, |
(45)2 screening, |
| (10)8 is |
(22)3 adherence |
(34)2 development |
(46)2 through |
| (11)8 on |
(23)3 approach |
(35)2 did |
(47)2 were |
| (12)7 outcomes |
(24)3 or |
(36)2 dose |
add keyword
--- WordNet output for treatment ---